DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for benign familial infantile epilepsy — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign familial infantile epilepsy maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign familial infantile epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel alpha subunit 8 (SCN8A) — SCN8A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3beta,14beta,17beta,25rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 25II · 2.5 Å · ligand (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en (9Z9). Experimental structure, not a prediction.
What the evidence adds up to
Benign familial infantile epilepsy is now called self-limited familial epilepsy with onset in infancy. It is an autosomal dominant disorder characterised by focal motor seizures that begin in infancy and remit during infancy or early childhood, with no neurodevelopmental complications. A positive family history usually suggests the genetic cause, but incomplete penetrance and de novo inheritance occur. The condition is caused by ion channel mutations, a mechanism shared with other monogenic epilepsies such as autosomal dominant nocturnal frontal lobe epilepsy and benign familial neonatal convulsions.
No clinical trial data for any drug treatment of benign familial infantile epilepsy are provided in these abstracts. The 2023 review describes diagnostic steps including genetic testing, management, and genetic counselling, but gives no specific drug names, response rates, or survival figures. The 1998 and 2011 papers discuss the genetic basis of idiopathic epilepsies generally, noting that in 60–65% of epilepsy patients the cause remains unknown, and that genetic predisposition accounts for about 40% of idiopathic cases. They do not address treatment outcomes for this specific syndrome.
The abstracts contain no evidence of drug repurposing, no comparative efficacy data, and no results from any interventional study. There is no mention of antiseizure medications, their effectiveness, or adverse effects in this population. The natural history of spontaneous seizure remission is described, but no data quantify how often or how quickly this occurs.
What is missing is any clinical trial testing a specific drug for this syndrome, any randomised or controlled study of treatment, and any stratification of patients by genotype or seizure severity. Without such evidence, no drug can be claimed to alter the course of the disease. Funding for a prospective, genetically stratified trial would be needed to determine whether any existing medication improves outcomes beyond the expected self-limited course.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 1998 · 29 citations
New insights into the molecular and genetic mechanisms underlying idiopathic epilepsies
AbstractFor many years, idiopathic epilepsies have been known to have a strong genetic background. In most subtypes, the mode of inheritance appears to be complex, with only some rare idiopathic epilepsies being monogenic disorders. Thus far, several gene loci have been reported for the common subtypes, such as juvenile myoclonic epilepsy, but the results of linkage studies in independent samples have often been conflicting. Recently, the gene defects underlying two monogenic epilepsies, autosomal dominant nocturnal frontal lobe epilepsy and benign familial neonatal convulsions, have been identified. Both diseases are caused by ion channel mutations, a similarity which may shed light on the understanding of the basic mechanisms of epileptogenesis.
AbstractDespite difficulties in precisely identifying and classifying infantile seizures, most infantile epilepsy syndromes can be classified, at least in broad categories. Infants with intractable epilepsy, however, may be difficult to accurately classify. These patients have complex presentations that do not easily allow labeling into "focal" or "generalized" categories. Within each category of infantile epilepsy, there appear to be benign and severe forms. Classifications based on semiology may be easier to use for all infants with epilepsy. At least three broad categories of epilepsy can be identified: infants with myoclonic seizures, infants with spasms, and infants with focal seizures. Within each category benign and severe presentations exist, with clearly defined, unique features. Whether the various presentations of epilepsy in infants can be cleanly separated into these categories, or need to be considered as points along a biologic spectrum, will require further research.
Epileptic Disorders · 2023 · 21 citations · open access
ILAE Genetic Literacy Series: Self‐limited familial epilepsy syndromes with onset in neonatal age and infancy
AbstractThe self-limited (familial) epilepsies with onset in neonates or infants, formerly called benign familial neonatal and/or infantile epilepsies, are autosomal dominant disorders characterized by neonatal- or infantile-onset focal motor seizures and the absence of neurodevelopmental complications. Seizures tend to remit during infancy or early childhood and are therefore called "self-limited". A positive family history for epilepsy usually suggests the genetic etiology, but incomplete penetrance and de novo inheritance occur. Here, we review the phenotypic spectrum and the genetic architecture of self-limited (familial) epilepsies with onset in neonates or infants. Using an illustrative case study, we describe important clues in recognition of these syndromes, diagnostic steps including genetic testing, management, and genetic counseling.
Neurologia i Neurochirurgia Polska · 2011 · 2 citations
Zaburzenia czynności kanałów jonowych w patogenezie padaczek idiopatycznych
AbstractPomimo postępów diagnostyki nadal u ok. 60–65% chorych nie można jednoznacznie ustalić przyczyny padaczki. W tej grupie chorych główną rolę odgrywają przypuszczalnie czynniki genetyczne. Uważa się, że u ok. 40% pacjentów predyspozycja genetyczna odpowiada za występowanie padaczek, określanych mianem „idiopatycznych”. Podłoże genetyczne padaczki potwierdzają liczne przykłady rodzinnie występujących zespołów padaczkowych. Należą do nich dziedziczona autosomalnie dominująco padaczka czołowa z napadami nocnymi oraz młodzieńcza padaczka miokloniczna. Obydwie formy padaczek uwarunkowane są mutacjami genów dla podjednostek neuronalnego receptora nikotynowego dla acetylocholiny. Postęp genetyki stworzył szansę dokładniejszego zrozumienia epileptogenezy na poziomie molekularnym, co ułatwia rozpoznanie oraz stwarza bardziej racjonalne podstawy leczenia i zapobiegania tej postaci padaczki. Despite advances in diagnostics, the cause of epilepsy has still not been unequivocally determined in 60-65% of patients. In this group of patients, genetic factors probably play the main role. It is thought that genetic predisposition is responsible for the occurrence of so-called “idiopathic” forms of epilepsy in about 40% of patients. The genetic basis of epilepsy has been substantiated by numerous examples of familial forms of epileptic syndromes. Among these, autosomal dominant nocturnal frontal lobe epilepsy and juvenile myoclonic epilepsy can be mentioned. Mutations in the neuronal nicotinic acetylcholine receptor subunit genes are responsible for both these epilepsies. Recent advances in molecular genetics have provided the means for better understanding of human epileptogenesis at a molecular level, which facilitates clinical diagnosis and provides a more rational basis for therapy and prevention of this form of epilepsy.
Dynamic electro‐clinical features in Guanidinoacetate N‐methyltransferase deficiency: A familial case series
AbstractGuanidinoacetate N-methyltransferase deficiency is an inborn error of creatine metabolism, responsible for the absent conversion of guanidinoacetic acid into creatine, resulting in cerebral creatine deficit. It could present a variety of symptoms such as neurodevelopmental delay, epilepsy, movement disorder (ataxia, dystonia, and chorea), and behavioral disturbances. After intellectual disability, epilepsy is the second most frequent expression of the disorder, usually arising during infancy with febrile seizures that are typically followed by generalized seizures and electroencephalographic anomalies. Herein, we describe three siblings with the same homozygous truncating variant in GAMT, all of whom showed significant global developmental delay during early infancy. The eldest two developed initially neglected atypical absences, preceded by focal motor seizures in the older brother, with complete remission with antiseizure medications and dietary treatment. Despite seizure freedom, during follow-up, both developed overt focal epileptiform discharges that have persisted after 2 years of creatine supplementation. Neither seizures nor electroencephalographic abnormalities were noted in the youngest brother who took advantage of an earlier diagnosis and treatment. The dynamic electroclinical pattern we observed has never been reported beforehand. Further studies are needed to assess the long-term prognosis of epilepsy in patients who have introduced dietary treatment after the seizure onset. PLAIN LANGUAGE SUMMARY: GAMT deficiency is a rare genetic disorder that prevents the brain from getting enough creatine, leading to developmental delay, seizures, movement disorders, and behavior problems. This condition often starts in infancy with seizures in fever and can be partially limited by creatine supplementation. In this paper, we present three siblings with the same mutation. The older two had seizures that improved with treatment, but their brain activity remained abnormal. The youngest, diagnosed and treated earlier with supplementation, did not develop epilepsy. More research is needed to understand electro-clinical features of this condition and the long-term effects of early or late dietary treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
